- ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugA new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.Fierce Biotech · 1d ago↗ source
- Capricor's DMD therapy lacks efficacy, FDA says ahead of adcommThe FDA is again questioning the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday. The agency's review team said it…Endpoints · 1d ago↗ source
- Six wellness peptides win backing from FDA advisory committeeAfter two days of meetings, an FDA advisory committee last week voted to lift restrictions on six popular health and wellness peptides, setting aside FDA staff concerns about a lack of safety and e…